Codexis to Report Third Quarter 2022 Financial Results on November 3
October 20 2022 - 4:05PM
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company
enabling the promise of synthetic biology, today announced that it
will report its financial results for the third quarter of 2022 on
Thursday, November 3, 2022, following the close of market. Codexis
management will host a conference call and webcast at 4:30 p.m.
Eastern Time to discuss the Company’s financial results and provide
a business update.
Participants may access the live webcast on the
Codexis Investor Relations website, where it will be archived for
90 days. The live call can be accessed by dialing (877) 705-2976
(domestic) or (201) 689-8798 (international), conference
ID #13732962. A replay of the call will be
available for 48 hours by dialing (877) 660-6853 (domestic) or
(201) 612-7415 (international), access ID #13726635.
About CodexisCodexis is a
leading enzyme engineering company leveraging its proprietary
CodeEvolver® platform to discover and develop novel, high
performance enzymes and biotherapeutics. Codexis enzymes have
applications in the sustainable manufacturing of pharmaceuticals,
food, and industrial products; in the creation of the next
generation of life science tools; and as gene therapy and oral
enzyme therapies. The Company’s unique performance enzymes drive
improvements such as: reduced energy usage, waste generation and
capital requirements; higher yields; higher fidelity diagnostics;
and more efficacious therapeutics. Codexis enzymes enable the
promise of synthetic biology to improve the health of people and
the planet. For more information, visit www.codexis.com.
Forward-Looking Statements To
the extent that statements contained in this press release are not
descriptions of historical facts regarding Codexis, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
You should not place undue reliance on these forward-looking
statements because they involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond
Codexis’ control and that could materially affect actual results.
Additional information about factors that could materially affect
actual results can be found in Codexis’ Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on
February 28, 2022 and in Codexis’ Quarterly Report on Form 10-Q
filed with the SEC on August 5, 2022, including under the caption
“Risk Factors,” and in Codexis’ other periodic reports filed with
the SEC. Codexis expressly disclaims any intent or obligation to
update these forward-looking statements, except as required by
law.
Investor Relations Contact:Argot
PartnersBrendan Strong/Carrie McKim(212)
600-1902Codexis@argotpartners.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024